also showed that the presence of the examined preexisting antibodies (Abs), such as rheumatoid factor (RF), anti-nuclear antibody (ANA), anti-thyroglobulin (Tg) Ab, and anti-thyroid peroxidase (TPO) Ab before ICI therapy was associated with the development of irAEs in patients with non-small-cell lung cancer (NSCLC).2 This evidence concerns the gene TPO and non-small cell lung carcinoma.